Organon & Co.(OGN)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Organon & Co. (OGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OGN at 50.5/100 on a 32-signal composite quality model, placing it at rank #1,594 of 2,961 stocks — the bottom half of the AI-ranked universe. OGN scores in the top quartile across earnings quality (91.9), institutional flow (91.4), revenue scale (80.6). Areas of concern include revenue growth (19.4) and profitability (31.5), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Organon & Co. reports quarterly revenue of $1.6B, net income of $108.0M, an operating margin of 11.8%. Top institutional holders of OGN by reported 13-F value include BlackRock, Pentwater Capital Management, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. OGN trades on the NYSE exchange and files with the SEC under CIK 1821825. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organon & Co. directly from SEC EDGAR.